The Orally Active Noncompetitive AMPAR Antagonist Perampanel Attenuates Focal Cerebral Ischemia Injury in Rats
- 11 April 2017
- journal article
- research article
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 38 (2) , 459-466
Abstract
Inhibition of ionotropic glutamate receptors (iGluRs) is a potential target of therapy for ischemic stroke. Perampanel is a potent noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptor (AMPAR) antagonist with good oral bioavailability and favorable pharmacokinetic properties. Here, we investigated the potential protective effects of perampanel against focal cerebral ischemia in a middle cerebral artery occlusion (MCAO) model in rats. Oral administration with perampanel significantly reduced MCAO-induced brain edema, brain infarct volume, and neuronal apoptosis. These protective effects were associated with improved functional outcomes, as measured by foot-fault test, adhesive removal test, and modified neurological severity score (mNSS) test. Importantly, perampanel was effective even when the administration was delayed to 1 h after reperfusion. The results of enzyme-linked immunosorbent assay (ELISA) showed that perampanel significantly decreased the expression of pro-inflammatory cytokines IL-1β and TNF-α, whereas it increased the levels of anti-inflammatory cytokines IL-10 and TGF-β1 after MCAO. In addition, perampanel treatment markedly decreased the expression of inducible nitric oxide synthase (iNOS) and neuronal nitric oxide synthase (nNOS), and also inhibited nitric oxide (NO) generation in MCAO-injured rats at 24 and 72 h after reperfusion. In conclusion, this study demonstrated that the orally active AMPAR antagonist perampanel protects against experimental ischemic stroke via regulating inflammatory cytokines and NOS pathways.Keywords
This publication has 43 references indexed in Scilit:
- Perampanel approved for epilepsyAmerican Journal of Health-System Pharmacy, 2012
- A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampusNeurochemistry International, 2012
- Inflammatory Cytokines in Experimental and Human StrokeJournal of Cerebral Blood Flow & Metabolism, 2012
- Inhibition of Sevoflurane Postconditioning Against Cerebral Ischemia Reperfusion-Induced Oxidative Injury in RatsMolecules, 2011
- The selective mGluR5 agonist CHPG protects against traumatic brain injury in vitro and in vivo via ERK and Akt pathwayInternational Journal of Molecular Medicine, 2011
- Neuroprotection for ischemic stroke: Past, present and futureNeuropharmacology, 2008
- TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative diseaseJournal of Neuroinflammation, 2008
- 1,026 Experimental treatments in acute strokeAnnals of Neurology, 2006
- Postischemic Gene Transfer of Interleukin-10 Protects Against Both Focal and Global Brain IschemiaCirculation, 2005
- Reduction of Inflammatory Response in the Mouse Brain With Adenoviral-Mediated Transforming Growth Factor-β1 ExpressionStroke, 2001